Intranasal Ketamine With Dexmedetomidine for the Treatment of Children With Autism Spectrum Disorder
Status:
Recruiting
Trial end date:
2023-12-30
Target enrollment:
Participant gender:
Summary
Autism spectrum disorder (ASD) is a life-long neurodevelopmental disorder characterized by
qualitative abnormalities in reciprocal social interactions and patterns of communication,
and by a restricted, stereotyped, repetitive repertoire of interests and activities. The use
of medications in adolescents and young adults with ASD is extremely common. However, few
data address the effectiveness and harms of medications specifically in this population.
The purpose of the study is to determine the efficacy and safety of intranasal ketamine with
dexmedetomidine in children with ASD.